Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$25.04 +3.46%

+$0.64 today

Market cap
$1.70B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.27M

Average 0.71M

Returns on capital

Zenas BioPharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-156.0%

avg -31.9%

ROIC

-65.6%

avg -88.5%

ROA

-98.5%

avg -88.8%

Analysis

ROIC is currently the strongest return metric at -65.6% versus its period average of -88.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Leon Oliver Moulder Jr.

Founder, CEO & ChairmanUSD 891.8K69——

Joseph L. Farmer

COO, President, Principal Financial Officer & Principal Accounting OfficerUSD 877.5K54175.00K0.39%

Jennifer A. Fox

Chief Business Officer & Chief Financial OfficerUSD 856.02K54125.00K0.28%

Lisa von Moltke

Head of Research & Development and Chief Medical Officer.USD 759.57K67150.00K0.34%

Jerald Korn

Chief Legal and Strategy Officer—47——

Abigail Lee Gray

Director of Investor Relations————

Haley Laken

Chief Scientific Officer————

Heinrich Schlieker

Chief Technical Officer————

Jeffrey Held

Chief Legal Officer—57——

Caroline Chevalier

Chief Administrative Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 15, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

17

$11.42M

Sells

0

$0.00

Net Transaction Value

+$11.42M

Net buying

Most Active

MOULDER LEON O JR

9 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 18, 26

MOULDER LEON O JR

Indirect

Buy$1M
Apr 29, 26

MOULDER LEON O JR

Indirect

Buy$616.7K
Apr 28, 26

MOULDER LEON O JR

Indirect

Buy$450.5K
Mar 31, 26

Lu Hongbo

Indirect

Buy$70.2K
Mar 31, 26

Fairmount Funds Management LLC

Indirect

Buy$3M
Mar 31, 26

MOULDER LEON O JR

Indirect

Buy$656.5K
Mar 31, 26

Lu Hongbo

Indirect

Buy$1.5M
Mar 30, 26

MOULDER LEON O JR

Indirect

Buy$364.6K
Feb 13, 26

Allen Patricia L

Direct

Buy$109.7K
Feb 12, 26

Allen Patricia L

Direct

Buy$132.5K

1–10 of 17

Summary

Insiders reported 17 buys worth $11.42M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $11.42M. MOULDER LEON O JR was the most active insider with 9 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
+122.7% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Forward estimates point to Revenue at +122.7% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Zenas BioPharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ZBIO's management, answered from reported figures.

Who manages ZBIO?

Zenas BioPharma, Inc. (ZBIO) lists 10 active executives. The top listed executive is Jerald Korn, Chief Legal and Strategy Officer.

Are ZBIO insiders buying or selling?

Recent insider activity shows net buying of $196.14M.